• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

New drug promising for psoriatic arthritis

An oral phosphodiesterase 4 inhibitor may offer significant improvement in signs and symptoms of psoriatic arthritis, according to preliminary trial data.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
Related Content
Suicide Risk Management Crucial in Dermatological Care
May 22nd 2025

Suicide Risk Management Crucial in Dermatological Care

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Quoin Receives FDA Clearance for Second Netherton Trial
May 22nd 2025

Quoin Receives FDA Clearance for Second Netherton Trial

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
March 31st 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial
May 22nd 2025

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome
May 22nd 2025

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome

© 2025 MJH Life Sciences

All rights reserved.